Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of GMC-252 in Healthy Men and Type 2 Diabetics
NCT02744820Phase 1Terminated
- Sponsor
- Genmedica Therapeutics
- Start
- Apr 2016
- Primary completion
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GMC-252 in type 2 diabetes mellitus (T2DM) (4 cohorts), sponsored by Genmedica Therapeutics. Primary endpoint: Number of Participants with Serious and Non-Serious Adverse Events at 42 days. Started Apr 2016; status: terminated.
02
Drugs
GMC-252
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02744820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02744820.